Register entryRepackager / relabeller
Legacy Pharma Inc SEZC
- Registered sites
- 1
- Drug products
- 0
- Live patents
- 74
- Countries
- 1
- Base
- CYM
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Labelling
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Legacy Pharma Inc. SEZC | George TownCYM | Labelling | 3038135133 |
Exclusivity
Patents
74Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| BRISDELLE | PAROXETINE MESYLATE | Apr 2029 |
| ESBRIET | PIRFENIDONE | Sept 2026 |
| ESBRIET | PIRFENIDONE | Dec 2027 |
| ESBRIET | PIRFENIDONE | May 2028 |
| ESBRIET | PIRFENIDONE | Apr 2029 |
| ESBRIET | PIRFENIDONE | Jan 2030 |
| ESBRIET | PIRFENIDONE | Aug 2033 |
| ESBRIET | PIRFENIDONE | Mar 2037 |
| NAFTIN | NAFTIFINE HYDROCHLORIDE | Jan 2033 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.